Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $17.25.

A number of analysts recently commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly acquired 45,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average cost of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.89% of the stock is owned by insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at approximately $26,000. Tower Research Capital LLC TRC grew its holdings in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 2,274 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Enanta Pharmaceuticals in the first quarter worth $40,000. Intech Investment Management LLC purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth $58,000. Finally, Squarepoint Ops LLC acquired a new stake in Enanta Pharmaceuticals during the fourth quarter valued at $66,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $5.05 on Wednesday. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $17.24. The business’s fifty day moving average is $5.80 and its 200-day moving average is $7.00. The stock has a market cap of $107.73 million, a PE ratio of -1.02 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. Equities research analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.